<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01060072</url>
  </required_header>
  <id_info>
    <org_study_id>577</org_study_id>
    <nct_id>NCT01060072</nct_id>
  </id_info>
  <brief_title>Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery</brief_title>
  <official_title>A Randomized, Multicenter, Double-Masked, Parallel-Group Clinical Safety and Efficacy Evaluation of Loteprednol Etabonate, 0.5% Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to compare the safety and efficacy of loteprednol etabonate to
      vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of Anterior Chamber Cells.</measure>
    <time_frame>Visit 5 (Postoperative day 8)</time_frame>
    <description>Participants with complete resolution of anterior chamber cells(ACC). Cells were graded on a 0-4 scale, where 0=no cells and 4=&gt;30 cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 0 Pain</measure>
    <time_frame>Visit 5 (Postoperative day 8)</time_frame>
    <description>Participants with no pain, graded on a 0-5 scale, 0=no pain and 5=severe pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of Anterior Chamber Cells</measure>
    <time_frame>Visit 4-7 (postoperative day 3-18)</time_frame>
    <description>Participants with complete resolution of anterior chamber cells(ACC). Cells were graded on a 0-4 scale, where 0=no cells and 4=&gt;30 cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 0 Pain</measure>
    <time_frame>Visits 4-7 (Postoperative days 3-18)</time_frame>
    <description>Participants with no pain, graded on a 0-5 scale, 0= no pain and 5=severe pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of Anterior Chamber Flare</measure>
    <time_frame>Visit 4-7 (postoperative day 3-18)</time_frame>
    <description>Complete resolution of flare, scored on a scale of 0-4 were 0=none and 4=very severe.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">407</enrollment>
  <condition>Inflammation</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Loteprednol etabonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loteprednol etabonate 0.5% ophthalmic suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of loteprednol etabonate ophthalmic suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol etabonate</intervention_name>
    <description>Topical administration of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye four times a day (QID), postoperative day 1-14.</description>
    <arm_group_label>Loteprednol etabonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle of Loteprednol Etabonate</intervention_name>
    <description>Topical administration of vehicle of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye QID, postoperative day 1-14.</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are at least 18 years of age.

          -  Subjects who are candidates for routine, uncomplicated cataract surgery.

        Exclusion Criteria:

          -  Subjects who have known hypersensitivity or contraindication to the study drug or
             components.

          -  Subjects with a severe/serious ocular condition, or any other unstable medical
             condition, that in the investigator's opinion may preclude study treatment or
             follow-up.

          -  Subjects with elevated intraocular pressure (&gt;/=21mm Hg), uncontrolled glaucoma, or
             being treated for glaucoma in the study eye.

          -  Subjects who are monocular or have pinholed Snellen visual acuity (VA) 20/200 or worse
             in the non-study eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Trusso</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2010</study_first_submitted>
  <study_first_submitted_qc>February 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2010</study_first_posted>
  <results_first_submitted>September 20, 2011</results_first_submitted>
  <results_first_submitted_qc>December 8, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2012</results_first_posted>
  <last_update_submitted>December 8, 2011</last_update_submitted>
  <last_update_submitted_qc>December 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 22 enrolling sites; 2 in the European Union (EU) and 20 in the United States (US). First participant was enrolled on 2/19/2010 and last participant completed the study on 9/3/2010.</recruitment_details>
      <pre_assignment_details>A total of 407 participants, who were candidates for routine, uncomplicated cataract surgery, were enrolled in the study, 400 participants completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Loteprednol Etabonate</title>
          <description>Loteprednol etabonate 0.5% ophthalmic suspension</description>
        </group>
        <group group_id="P2">
          <title>Vehicle</title>
          <description>Vehicle of loteprednol etabonate ophthalmic suspension.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="206"/>
                <participants group_id="P2" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Acute cholecystitis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excluded Medications</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Loteprednol Etabonate</title>
          <description>Loteprednol etabonate 0.5% ophthalmic suspension</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>Vehicle of loteprednol etabonate ophthalmic suspension.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="206"/>
            <count group_id="B2" value="201"/>
            <count group_id="B3" value="407"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Intent to treat Population (ITT)</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.3" spread="9.66"/>
                    <measurement group_id="B2" value="69.4" spread="9.56"/>
                    <measurement group_id="B3" value="68.9" spread="9.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="193"/>
                    <measurement group_id="B3" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Resolution of Anterior Chamber Cells.</title>
        <description>Participants with complete resolution of anterior chamber cells(ACC). Cells were graded on a 0-4 scale, where 0=no cells and 4=&gt;30 cells</description>
        <time_frame>Visit 5 (Postoperative day 8)</time_frame>
        <population>Intention to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate</title>
            <description>Loteprednol etabonate 0.5% ophthalmic suspension</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of loteprednol etabonate ophthalmic suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Resolution of Anterior Chamber Cells.</title>
          <description>Participants with complete resolution of anterior chamber cells(ACC). Cells were graded on a 0-4 scale, where 0=no cells and 4=&gt;30 cells</description>
          <population>Intention to treat (ITT) population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Grade 0 Pain</title>
        <description>Participants with no pain, graded on a 0-5 scale, 0=no pain and 5=severe pain</description>
        <time_frame>Visit 5 (Postoperative day 8)</time_frame>
        <population>Intention to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate</title>
            <description>Loteprednol etabonate 0.5% ophthalmic suspension</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of loteprednol etabonate ophthalmic suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Grade 0 Pain</title>
          <description>Participants with no pain, graded on a 0-5 scale, 0=no pain and 5=severe pain</description>
          <population>Intention to treat (ITT) population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resolution of Anterior Chamber Cells</title>
        <description>Participants with complete resolution of anterior chamber cells(ACC). Cells were graded on a 0-4 scale, where 0=no cells and 4=&gt;30 cells</description>
        <time_frame>Visit 4-7 (postoperative day 3-18)</time_frame>
        <population>Intention to treat population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate</title>
            <description>Loteprednol etabonate 0.5% ophthalmic suspension</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of loteprednol etabonate ophthalmic suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Resolution of Anterior Chamber Cells</title>
          <description>Participants with complete resolution of anterior chamber cells(ACC). Cells were graded on a 0-4 scale, where 0=no cells and 4=&gt;30 cells</description>
          <population>Intention to treat population (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4 (Postoperative Day 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Postoperative Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Postoperative Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7 (Postoperative Day 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grade 0 Pain</title>
        <description>Participants with no pain, graded on a 0-5 scale, 0= no pain and 5=severe pain</description>
        <time_frame>Visits 4-7 (Postoperative days 3-18)</time_frame>
        <population>Intention to treat population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate</title>
            <description>Loteprednol etabonate 0.5% ophthalmic suspension</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of loteprednol etabonate ophthalmic suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Grade 0 Pain</title>
          <description>Participants with no pain, graded on a 0-5 scale, 0= no pain and 5=severe pain</description>
          <population>Intention to treat population (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4 (Postoperative Day 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Postoperative Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Postoperative Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7 (Postoperative Day 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resolution of Anterior Chamber Flare</title>
        <description>Complete resolution of flare, scored on a scale of 0-4 were 0=none and 4=very severe.</description>
        <time_frame>Visit 4-7 (postoperative day 3-18)</time_frame>
        <population>Intention to treat population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate</title>
            <description>Loteprednol etabonate 0.5% ophthalmic suspension</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of loteprednol etabonate ophthalmic suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Resolution of Anterior Chamber Flare</title>
          <description>Complete resolution of flare, scored on a scale of 0-4 were 0=none and 4=very severe.</description>
          <population>Intention to treat population (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4 (Postoperative Day 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Postoperative Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Postoperative Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7 (Postoperative Day 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Loteprednol Etabonate</title>
          <description>Loteprednol etabonate 0.5% ophthalmic suspension</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>Vehicle of loteprednol etabonate ophthalmic suspension.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Anterior Chamber Inflammation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="206"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tuyen Ong, MD, MRCOphth</name_or_title>
      <organization>Bausch &amp; Lomb Incorporated</organization>
      <phone>(973) 360-6389</phone>
      <email>tuyen.ong@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

